Impact BioMedical Inc.
IBO | AMEX
$3.80
-$0.07 (-1.81%)
At close: Oct 30, 2026, 4:00 PM ET
$3.80
$0.00 (0.00%)
After-hours:
Oct 30, 2026, 4:00 PM ET
Company Profile
Houston, Texas-based Impact BioMedical Inc., founded in 2018, focuses on discovering and developing innovative products and therapeutic options for both specialty biopharmaceuticals and consumer healthcare markets. The company features several key technologies: its "Linebacker" platform utilizes small molecule electrophilically enhanced polyphenol compounds with potential applications in treating cancer, inflammatory diseases, and neurological conditions. Additionally, "Laetose" technology, a unique blend of sugar and inositol, is designed to counteract the inflammatory and metabolic responses usually triggered by sugar consumption. Impact BioMedical also creates "functional fragrance formulations," which are a series of fragrances incorporating specialized botanical ingredients for antimicrobial purposes, or as active additives in items like insect repellents, cleaning products, personal care items, and fabrics. Rounding out its offerings is the "Equivir/Equivir G" technology, a distinctive mix of polyphenols that has exhibited antiviral properties, suitable for use in health supplements and medications.
Key Executives
| Name | Position |
|---|---|
| Frank D. Heuszel | Chairman & Chief Executive Officer |
| Mark J. Suseck | Chief Operating Officer |
| Todd D. Macko | Chief Financial Officer, Secretary & Treasurer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 24, 2026 | 4 | Filing |
| Sep 17, 2026 | 425 | Filing |
| Sep 17, 2026 | 8-K | Current Report |
| Sep 15, 2026 | 425 | Filing |
| Sep 15, 2026 | 8-K | Current Report |
| Aug 07, 2026 | 10-Q | Quarterly Report |
| May 12, 2026 | 10-Q | Quarterly Report |
| Apr 22, 2026 | S-8 POS | Filing |
| Apr 06, 2026 | S-8 POS | Filing |
| Mar 30, 2026 | 4 | Filing |
Impact BioMedical Inc.
| Country | United States |
| IPO Date | Sep 16, 2024 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 2 |
| CEO | Frank D. Heuszel |
Contact Details
1400 Broadfield Blvd. Houston,
Texas 77084 United States
Stock Details
| Ticker Symbol | IBO |
| Exchange | AMEX |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001834105 |
| CUSIP Number | 45259L304 |
| ISIN Number | US45259L3042 |
| SIC Code | 2834 |
Recent News
- 2 months ago / globenewswire.comImpact Biomedical Inc Announces Filing of Form F-4 Registration Statement in Connection with Proposed Merger with Zoar Ltd. (f/k/a Dr. Ashley's Limited)
- 2 months ago / globenewswire.comCORRECTED — Impact Biomedical Inc (NYSE: IBO) Announces 1 for 12.62 Reverse Stock Split to Pursue Completion of Merger with Zoar Limited (f/k/a Dr Ashleys Limited)
- 2 months ago / globenewswire.comImpact BioMedical Inc (NYSE American: IBO) Announces 1 for 12.62 Reverse Stock Split to Pursue Completion of Merger with Zoar Ltd. (previously Dr. Ashley's Ltd.
Add to Watchlist
Select watchlists to add or remove IBO